A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Epsium Enterprise Ltd. (EPSM) is planning to raise $6 million in an initial public offering on Wednesday, March 26th, IPO Scoop reports. The company will be issuing 1,300,000 shares at $4.00-$5.00 per ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

BofA lowered the firm’s price target on Ladder Capital (LADR) to $12.50 from $13 and keeps a Neutral rating on the shares.

BofA raised the firm’s price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm’s higher target reflects ...

The program offers all dosage strengths of the weight-loss medication at a reduced price of $499 per month ... Outsourcing Facilities Association (OFA) and FarmaKeio Superior Custom Compounding ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

The Outsourcing Facilities Association (OFA) alleged the agency was “abruptly depriving patients of much needed treatment and artificially raising drug prices.” Compounders had been allowed to ...

Grosslight’s price target of $27 implies a downside of ... Grosslight noted that the compounding group Outsourcing Facilities Association (OFA) has filed a notice to appeal a recent ruling ...

Epsium Enterprise Ltd. (EPSM) plans to raise $6 million in an initial public offering on the week of March 17th, IPO Scoop reports. The company will be issuing 1,300,000 shares at a price of $4.00-$5.